However, the majority of BC tumors present a low expression of HER2 (IHC 1+ or 2+, but FISH negative), and the recent report of NASBP B-47 shows that no survival benefit could be obtained from the combination of trastuzumab with chemotherapy among women with HER2-low-positive BC [13]. The gene discussed is ERBB2; the disease is breast cancer.